Financial Performance Summary

AstraZeneca Pharma India Limited reported its financial results for the quarter ended June 30, 2026 (Q1 FY2026-27). The company achieved total revenue from operations of INR 6,828 Mn, representing 30% year-over-year growth. This performance continues the company's track record of delivering consistent double-digit growth over the last five years.

Profit before exceptional item and tax stood at INR 510 Mn for the quarter. Profit after exceptional item and tax was INR 507 Mn. The company noted that the phrase "Profit after exceptional item and tax" appearing in the financial performance summary should be read as "Profit after exceptional item and before tax" (i.e., Profit before tax).

Performance Drivers and Business Context

The strong performance was driven by continued momentum across the company's core therapy areas: Oncology, Biopharmaceuticals (CVRM and R&I), and Rare Disease. This reflects the strength of the company's innovation-led strategy, disciplined execution, and focus on improving patient outcomes in India.

The company strengthened its portfolio through key regulatory approvals, expanded scientific engagement through targeted capability-building initiatives, and advanced strategic partnerships that support earlier diagnosis and broader access.

Key Regulatory Milestones

The company received three significant regulatory approvals during the quarter:

  • Acalabrutinib for Chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL): Approval for acalabrutinib in combination with venetoclax with or without obinutuzumab for previously untreated patients
  • Acalabrutinib for Mantle cell lymphoma (MCL): Approval for acalabrutinib in combination with bendamustine and rituximab for adult patients with previously untreated MCL who are not eligible for autologous stem cell transplant (ASCT)
  • Trastuzumab deruxtecan for HER2-positive breast cancer: Approval for trastuzumab deruxtecan in combination with pertuzumab for first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+ or ISH+) breast cancer

Strategic Initiatives

The company announced several strategic partnerships and initiatives:

  • Government of Telangana MoU - AI-enabled lung cancer screening: Signed a Memorandum of Understanding with the Government of Telangana to introduce AI-enabled lung cancer screening across public healthcare facilities. The collaboration will deploy Qure.ai's AI-powered chest X-ray solution to support clinicians in identifying high-risk pulmonary nodules. The initiative will roll out across 20 public health facilities in urban and rural settings and includes training and upskilling of healthcare professionals.
  • K+ Connect - Hyperkalaemia management: Launched a pan-India multidisciplinary initiative focused on advancing the management of hyperkalaemia among patients with heart failure and chronic kidney disease. The program brings together clinicians across specialties to support coordinated approach towards risk identification, monitoring and management.
  • India Coronary Conquest (ICC) 2026: Launched in collaboration with STEMI India, this is a clinician-led national complex PCI challenge designed to strengthen evidence-based learning and peer exchange among interventional cardiologists. The initiative aims to support capability building in advanced cardiovascular care through case-based learning.

Recognitions and Awards

The company received several awards during the quarter:

  • OPPI India Awards 2026: Medical Excellence Award for contributions to Rare Disease and Runner-up in Marketing Excellence category for Hyperkalaemia & Kidney Care initiative
  • ETHRWorld Employee Experience Awards 2026: Gold Award in Exceptional Employee Experience in Driving Business Impact category

Company Overview

AstraZeneca Pharma India Limited (AZPIL) is the listed operating company of AstraZeneca in India, focusing on discovery, development and commercialisation of prescription medicines across Oncology, Biopharmaceuticals and Rare Disease therapy areas. The company employs over 600 employees across India.

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director: "We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation."

Praveen Rao Akkinepally, Country President & Managing Director: "Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India."